Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.

Tadros AB, Moo TA, Stempel M, Zabor EC, Khan AJ, Morrow M.

Breast Cancer Res Treat. 2020 Jan 14. doi: 10.1007/s10549-019-05520-5. [Epub ahead of print]

PMID:
31938938
2.

Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?

Minami CA, Zabor EC, Gilbert E, Newman A, Park A, Jochelson MS, King TA, Pilewskie ML.

Ann Surg Oncol. 2020 Jan 2. doi: 10.1245/s10434-019-08126-9. [Epub ahead of print]

PMID:
31898097
3.

Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes.

Valero MG, Muhsen S, Moo TA, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini VS.

Ann Surg Oncol. 2020 Feb;27(2):344-351. doi: 10.1245/s10434-019-07948-x. Epub 2019 Dec 10.

PMID:
31823173
4.

Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.

Christian N, Zabor EC, Cassidy M, Flynn J, Morrow M, Gemignani ML.

Ann Surg Oncol. 2019 Nov 15. doi: 10.1245/s10434-019-08038-8. [Epub ahead of print]

PMID:
31732944
5.

Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.

Moo TA, Jochelson MS, Zabor EC, Stempel M, Raiss M, Mamtani A, Tadros AB, El-Tamer M, Morrow M.

Ann Surg Oncol. 2019 Dec;26(13):4238-4243. doi: 10.1245/s10434-019-07867-x. Epub 2019 Oct 3.

PMID:
31583546
6.

The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.

Valero MG, Zabor EC, Park A, Gilbert E, Newman A, King TA, Pilewskie ML.

Ann Surg Oncol. 2019 Sep 26. doi: 10.1245/s10434-019-07814-w. [Epub ahead of print]

PMID:
31559544
7.

Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.

Miller ME, Muhsen S, Zabor EC, Flynn J, Olcese C, Giri D, Van Zee KJ, Pilewskie M.

Ann Surg Oncol. 2019 Dec;26(13):4317-4325. doi: 10.1245/s10434-019-07796-9. Epub 2019 Sep 24.

PMID:
31552614
8.

Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines?

Mamtani A, Zabor EC, Rosenberger LH, Stempel M, Gemignani ML, Morrow M.

Ann Surg Oncol. 2019 Nov;26(12):3856-3862. doi: 10.1245/s10434-019-07751-8. Epub 2019 Aug 27.

PMID:
31456094
9.

Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.

Mamtani A, Nakhlis F, Downs-Canner S, Zabor EC, Morrow M, King TA, Van Zee KJ.

Ann Surg Oncol. 2019 Dec;26(13):4264-4271. doi: 10.1245/s10434-019-07693-1. Epub 2019 Aug 22.

PMID:
31440931
10.

Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy?

Walsh SM, Brennan SB, Zabor EC, Rosenberger LH, Stempel M, Lebron-Zapata L, Gemignani ML.

Ann Surg Oncol. 2019 Dec;26(13):4246-4253. doi: 10.1245/s10434-019-07647-7. Epub 2019 Aug 8.

PMID:
31396783
11.

Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study.

Benefield HC, Zabor EC, Shan Y, Allott EH, Begg CB, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1784-1791. doi: 10.1158/1055-9965.EPI-19-0365. Epub 2019 Aug 8.

PMID:
31395590
12.

A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction.

Flanagan MR, Zabor EC, Romanoff A, Fuzesi S, Stempel M, Mehrara BJ, Morrow M, Pusic AL, Gemignani ML.

Ann Surg Oncol. 2019 Oct;26(10):3133-3140. doi: 10.1245/s10434-019-07548-9. Epub 2019 Jul 24.

PMID:
31342397
13.

Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score.

Van Zee KJ, Zabor EC, Di Donato R, Harmon B, Fox J, Morrow M, Cody HS 3rd, Fineberg SA.

Ann Surg Oncol. 2019 Oct;26(10):3282-3288. doi: 10.1245/s10434-019-07537-y. Epub 2019 Jul 24.

PMID:
31342373
14.

Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.

Mamtani A, Zabor EC, Stempel M, Morrow M.

Ann Surg Oncol. 2019 Oct;26(10):3269-3274. doi: 10.1245/s10434-019-07536-z. Epub 2019 Jul 24.

PMID:
31342363
15.

Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma.

Grabenstetter A, Moo TA, Hajiyeva S, Schüffler PJ, Khattar P, Friedlander MA, McCormack MA, Raiss M, Zabor EC, Barrio A, Morrow M, Edelweiss M.

Am J Surg Pathol. 2019 Oct;43(10):1377-1383. doi: 10.1097/PAS.0000000000001311.

PMID:
31219817
16.

Does race predict survival for women with invasive breast cancer?

Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML.

Cancer. 2019 Sep 15;125(18):3139-3146. doi: 10.1002/cncr.32296. Epub 2019 Jun 17.

PMID:
31206623
17.

Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor.

Flanagan MR, Zabor EC, Stempel M, Mangino DA, Morrow M, Pilewskie ML.

Ann Surg Oncol. 2019 Jul;26(7):2127-2135. doi: 10.1245/s10434-019-07236-8. Epub 2019 Feb 27.

PMID:
30815800
18.

Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.

Spanheimer PM, Murray MP, Zabor EC, Stempel M, Morrow M, Van Zee KJ, Barrio AV.

Ann Surg Oncol. 2019 Jul;26(7):2136-2143. doi: 10.1245/s10434-019-07210-4. Epub 2019 Feb 19.

PMID:
30783853
19.

Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose?

Downs-Canner S, Zabor EC, Wind T, Cobovic A, McCormick B, Morrow M, Heerdt A.

Ann Surg Oncol. 2019 Apr;26(4):969-975. doi: 10.1245/s10434-018-07151-4. Epub 2019 Feb 8.

PMID:
30737670
20.

Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts.

Engel LS, Zabor EC, Satagopan J, Widell A, Rothman N, O'Brien TR, Zhang M, Van Den Eeden SK, Grimsrud TK.

Int J Cancer. 2019 Nov 1;145(9):2360-2371. doi: 10.1002/ijc.32175. Epub 2019 Feb 14.

PMID:
30701531
21.

Differences between screen-detected and interval breast cancers among BRCA mutation carriers.

Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.

Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.

PMID:
30673971
22.

Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics.

Silk MT, Mikkilineni N, Silk TC, Zabor EC, Ostrovnaya I, Hakimi AA, Hsieh JJ, Ziv E, Rekhtman N, Solomon SB, Durack JC.

Anal Cell Pathol (Amst). 2018 Dec 10;2018:2898962. doi: 10.1155/2018/2898962. eCollection 2018.

23.

Guidelines for Reporting of Statistics for Clinical Research in Urology.

Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, Delfino K, Fan Y, Zhao Z, Koyama T, Hollenbeck B, Qin R, Zahnd W, Zabor EC, Kattan MW, Vickers AJ.

J Urol. 2019 Mar;201(3):595-604. doi: 10.1097/JU.0000000000000001. No abstract available.

PMID:
30633111
24.

Guidelines for Reporting of Statistics for Clinical Research in Urology.

Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, Delfino K, Fan Y, Zhao Z, Koyama T, Hollenbeck B, Qin R, Zahnd W, Zabor EC, Kattan MW, Vickers AJ.

Eur Urol. 2019 Mar;75(3):358-367. doi: 10.1016/j.eururo.2018.12.014. Epub 2018 Dec 21.

PMID:
30580902
25.

Guidelines for reporting of statistics for clinical research in urology.

Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, Delfino K, Fan Y, Zhao Z, Koyama T, Hollenbeck B, Qin R, Zahnd W, Zabor EC, Kattan MW, Vickers AJ.

BJU Int. 2019 Mar;123(3):401-410. doi: 10.1111/bju.14640. Epub 2019 Jan 20.

PMID:
30537407
26.

Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?

Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML.

Ann Surg Oncol. 2019 Feb;26(2):336-342. doi: 10.1245/s10434-018-7004-6. Epub 2018 Nov 30.

PMID:
30506175
27.

ASO Author Reflections: Careful Development and Thoughtful Interpretation are Needed when Developing Online Prognostic Tools.

Zabor EC.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):916-917. doi: 10.1245/s10434-018-6987-3. Epub 2018 Nov 1. No abstract available.

28.

Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?

Romanoff A, Zabor EC, Petruolo O, Stempel M, El-Tamer M, Morrow M, Barrio AV.

Cancer. 2018 Nov 15;124(22):4314-4321. doi: 10.1002/cncr.31757. Epub 2018 Oct 11.

29.

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.

Cronin PA, Romanoff A, Zabor EC, Stempel M, Eaton A, Smyth LM, Ho AY, Morrow M, El-Tamer M, Gemignani ML.

Ann Surg Oncol. 2018 Dec;25(13):3858-3866. doi: 10.1245/s10434-018-6767-0. Epub 2018 Oct 8.

30.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
31.

A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction.

Romanoff A, Zabor EC, Stempel M, Sacchini V, Pusic A, Morrow M.

Ann Surg Oncol. 2018 Oct;25(10):2909-2916. doi: 10.1245/s10434-018-6585-4. Epub 2018 Jul 2.

32.

Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.

Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, Moskowitz CS, Matsoukas K, Iyengar NM, Dang CT, Jones LW.

J Clin Oncol. 2018 Aug 1;36(22):2297-2305. doi: 10.1200/JCO.2017.77.5809. Epub 2018 Jun 12.

33.

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE.

Urol Oncol. 2018 Jul;36(7):345-346. doi: 10.1016/j.urolonc.2018.05.011. Epub 2018 May 30.

PMID:
29859727
34.

Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival.

Francis JH, Levin AM, Zabor EC, Gobin YP, Abramson DH.

PLoS One. 2018 May 23;13(5):e0197081. doi: 10.1371/journal.pone.0197081. eCollection 2018.

35.

Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio A, Morrow M.

Ann Surg Oncol. 2018 Jun;25(6):1488-1494. doi: 10.1245/s10434-018-6429-2. Epub 2018 Mar 23.

36.

RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY".

Begg CB, Seshan VE, Zabor EC.

Am J Epidemiol. 2018 May 1;187(5):1129-1130. doi: 10.1093/aje/kwy032. No abstract available.

37.

Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.

Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS.

Ann Surg Oncol. 2018 Aug;25(8):2172-2177. doi: 10.1245/s10434-018-6370-4. Epub 2018 Feb 22.

38.

The Effect of Patient and Surgical Characteristics on Renal Function After Partial Nephrectomy.

Winer AG, Zabor EC, Vacchio MJ, Hakimi AA, Russo P, Coleman JA, Jaimes EA.

Clin Genitourin Cancer. 2018 Jun;16(3):191-196. doi: 10.1016/j.clgc.2017.11.006. Epub 2017 Dec 6.

39.

Does response to neo-adjuvant chemotherapy impact breast reconstruction?

Cassidy MR, Zabor EC, Stempel M, Mehrara B, Gemignani ML.

Breast J. 2018 Jul;24(4):567-573. doi: 10.1111/tbj.12977. Epub 2018 Jan 8.

40.

Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma.

Lee BH, Zabor EC, Tennenbaum D, Furberg H, Benfante N, Coleman JA, Jaimes EA, Russo P.

World J Urol. 2018 Feb;36(2):257-263. doi: 10.1007/s00345-017-2139-9. Epub 2017 Dec 5.

41.

Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study.

Zabor EC, Furberg H, Lee B, Campbell S, Lane BR, Thompson RH, Antonio EC, Noyes SL, Zaid H, Jaimes EA, Russo P.

J Urol. 2018 Apr;199(4):921-926. doi: 10.1016/j.juro.2017.10.027. Epub 2017 Oct 21.

42.

Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2019 Jul;5(4):642-649. doi: 10.1016/j.euf.2017.09.008. Epub 2017 Sep 24.

PMID:
28951115
43.

Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.

Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, Matasar MJ, Steingart R, Vickers AJ, Svenssen Munksgaard P, Oeffinger KC, Johansen C.

J Clin Oncol. 2017 Dec 1;35(34):3837-3843. doi: 10.1200/JCO.2017.72.4211. Epub 2017 Sep 18.

44.

MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.

Weber JJ, Jochelson MS, Eaton A, Zabor EC, Barrio AV, Gemignani ML, Pilewskie M, Van Zee KJ, Morrow M, El-Tamer M.

J Am Coll Surg. 2017 Dec;225(6):740-746. doi: 10.1016/j.jamcollsurg.2017.08.027. Epub 2017 Sep 15.

45.

Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.

Gentile LF, Plitas G, Zabor EC, Stempel M, Morrow M, Barrio AV.

Ann Surg Oncol. 2017 Dec;24(13):3896-3902. doi: 10.1245/s10434-017-6085-y. Epub 2017 Sep 15.

46.

Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients.

Cho GY, Gennaro L, Sutton EJ, Zabor EC, Zhang Z, Giri D, Moy L, Sodickson DK, Morris EA, Sigmund EE, Thakur SB.

Eur J Radiol Open. 2017 Aug 18;4:101-107. doi: 10.1016/j.ejro.2017.07.002. eCollection 2017.

47.

Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.

Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.

Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.

48.

The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.

Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M.

Ann Surg Oncol. 2017 Nov;24(12):3527-3533. doi: 10.1245/s10434-017-6016-y. Epub 2017 Jul 31.

49.

Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.

Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA.

Eur Urol Focus. 2017 Oct;3(4-5):421-427. doi: 10.1016/j.euf.2016.06.015. Epub 2016 Jul 16.

50.

A comparison of statistical methods for the study of etiologic heterogeneity.

Zabor EC, Begg CB.

Stat Med. 2017 Nov 10;36(25):4050-4060. doi: 10.1002/sim.7405. Epub 2017 Jul 26.

Supplemental Content

Loading ...
Support Center